SLC22A2 and colorectal cancer: Decreased expression of SLC22A2 (OCT2) has been reported to be associated with decreased cytotoxicity to oxaliplatin in vitro (31); however, this transporter is primarily expressed in renal cells and in dorsal root ganglia, suggesting a role in peripheral neurotoxicity as opposed to uptake by colorectal cancer cells (32).